-

VB Spine Announces Successful First Clinical Cases of Vulcan™ Spinal System

Milestone marks entry into Limited Market Release and builds momentum toward broader commercialization

NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”), today announced the successful completion of the first clinical cases utilizing the Vulcan™ Spinal System for thoracolumbar fixation. The milestone marks the system’s entry into Limited Market Release and represents a significant step forward in the company’s strategy to expand its next-generation implant portfolio.

At VB Spine, everything starts with the patient.

Share

The first case was performed on February 26 at MedStar Georgetown University Hospital in Washington, DC, marking the official clinical debut of the Vulcan Spinal System.

Continuing the system’s strong early clinical momentum, two additional surgeons at MedStar Georgetown University Hospital performed procedures following the first case. With three successful cases completed across two days, the early experience reflects an encouraging and energized start for the system.

The Vulcan Degenerative System was engineered to support fixation strength, surgical precision, and procedural efficiency while maintaining a streamlined workflow for the operating room. Designed in collaboration with surgeons, the system integrates advanced implant geometry and instrumentation intended to address the evolving demands of modern spine surgery.

“At VB Spine, everything starts with the patient,” said Marc Viscogliosi, co-CEO of VB Spine. “Moments like this represent patients placing their trust in innovation, in their surgeons, and in all of us behind the scenes. I’m proud of what the VB Spine team has been able to accomplish in this short period of time. We are grateful to the surgeons who partnered with us to develop this system and honored to support solutions designed to improve patient outcomes and advance spine care.”

The Limited Market Release phase will focus on gathering continued clinical feedback, supporting surgeon adoption, and ensuring operational readiness ahead of full commercial launch.

Regulatory and Availability

The Vulcan™ Spinal System is cleared by FDA for sale in the United States. It is intended for use in spinal fixation procedures to provide stabilization and support as part of a comprehensive surgical construct as an adjunct to fusion.

Forward-Looking Statements

Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law.

About VB Spine

VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships, and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit www.vbspineco.com.

Contacts

For media inquiries only:
spinecommunications@vbspineco.com

VB Spine LLC


Release Versions

Contacts

For media inquiries only:
spinecommunications@vbspineco.com

Social Media Profiles
More News From VB Spine LLC

VB Spine Receives FDA Clearances of Expanded Indications for Vitoss® Bone Graft Substitute and Interbody Cage Portfolio

NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”) today announced that the U.S. Food and Drug Administration (FDA) granted two 510(k) clearances that expand the indications for its Vitoss® Bone Graft Substitute and interbody cage portfolio. The clearances allow Vitoss® to be used in the intervertebral disc space with interbody cages and expand the indications for VB Spine’s interbody cages to include use with bone void fillers cleared for use in intervertebral body fusion procedures, includi...

VB Spine’s European Distribution Center Begins Shipping Orders Across Europe

NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”), a global, family-owned spine company, today announced that its European Distribution Center began shipping orders across Europe this month; the distribution center began accepting orders on June 1, 2026. Now that the center is fully operational, it serves as the primary center for VB Spine product distribution to customers in Europe. “The center allows us to support our customers more effectively by reducing fulfillment and response times,”...

VB Spine to Acquire CT-Fluoro Technology for Spine Applications from Augmedics

NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”) today announced it has entered into a definitive agreement to acquire the exclusive rights to Augmedics’ CT-to-fluoroscopy (CT-Fluoro) technology for spine applications.This acquisition reflects VB Spine's ongoing investment in innovative technologies, building on the acquisition of exclusive rights to the Augmedics’ xvision Spine System® platform in April. With CT-Fluoro technology, surgeons are able to register a patient's preoperative CT sc...
Back to Newsroom